{
    "organizations": [],
    "uuid": "ed014c5fd4e6117b6eb390667262fb3005606cf3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ohr-pharmaceutical-announces-effic/brief-ohr-pharmaceutical-announces-efficacy-results-from-the-mako-study-in-wet-amd-idUSFWN1P00FM",
    "ord_in_thread": 0,
    "title": "BRIEF-Ohr Pharmaceutical Announces Efficacy Results From The Mako Study In Wet-Amd",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 08 AM / in 5 minutes BRIEF-Ohr Pharmaceutical Announces Efficacy Results From The Mako Study In Wet-Amd Reuters Staff \nJan 5 (Reuters) - Ohr Pharmaceutical Inc: \n* OHR PHARMACEUTICAL ANNOUNCES EFFICACY RESULTS FROM THE MAKO STUDY IN WET-AMD \n* OHR PHARMACEUTICAL INC - ‍TOPLINE DATA FROM MAKO STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT​ \n* OHR PHARMACEUTICAL INC - “WE ARE VERY DISAPPOINTED WITH OUTCOME OF MAKO STUDY” \n* OHR PHARMACEUTICAL INC - ‍INTEND TO EVALUATE STRATEGIC ALTERNATIVES TO “MAXIMIZE SHAREHOLDER VALUE”​ \n* OHR PHARMA - SUBJECTS RECEIVING SQUALAMINE COMBINATION THERAPY ACHIEVED MEAN GAIN OF 8.33 LETTERS FROM BASELINE VERSUS 10.58 FROM LUCENTIS MONOTHERAPY Source text for Eikon: Further company coverage:",
    "published": "2018-01-05T13:07:00.000+02:00",
    "crawled": "2018-01-05T13:20:43.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "minute",
        "pharmaceutical",
        "announces",
        "efficacy",
        "result",
        "mako",
        "study",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "ohr",
        "pharmaceutical",
        "inc",
        "ohr",
        "pharmaceutical",
        "announces",
        "efficacy",
        "result",
        "mako",
        "study",
        "ohr",
        "pharmaceutical",
        "inc",
        "data",
        "mako",
        "study",
        "meet",
        "primary",
        "efficacy",
        "ohr",
        "pharmaceutical",
        "inc",
        "disappointed",
        "outcome",
        "mako",
        "study",
        "ohr",
        "pharmaceutical",
        "inc",
        "evaluate",
        "strategic",
        "alternative",
        "maximize",
        "shareholder",
        "value",
        "ohr",
        "pharma",
        "subject",
        "receiving",
        "squalamine",
        "combination",
        "therapy",
        "achieved",
        "mean",
        "gain",
        "letter",
        "baseline",
        "versus",
        "lucentis",
        "monotherapy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}